A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease.

Abstract

Nine outpatients meeting research criteria for probable Alzheimer's disease who had psychosis or behavioral disturbance participated in a single-blind, placebo-controlled pilot study. Oral haloperidol in doses of 1 to 5 mg daily improved target symptoms, confirmed by double-blind ratings of videotaped interviews. Patients could not be maintained on more… (More)

Topics

  • Presentations referencing similar topics